GLP-1 receptor modulators

A compound having the structure of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• J is null or has the structure:
• each of X1A, X1B, X1C, X1D, X1E, X1F and X1G is C, CH or N;
• X1H is O or S;
• X1J is CH2 or NH;
• R1 is H, alkyl or alkoxy;
• Y is —C(O)—, —CH2—, —C(O)—CH2—, —CH2—C(O)—, —C(O)—(CRaRb)n—N(Rc)—C(O)—(CRaRb)n—, —C(O)—(CRaRb)n—N(Rd)where Rd may form a fused ring with J or with a fused J-R4—W1 ring system, —C(O)—(CRaRb)n—N(Rc)—C(O)—(CRaRb)n—N(Rc)—S(O)k—(CRaRb)n—, —C(O)—(CRaRb)n—N(Rc)—C(O)—(CRaRb)—N(Rd)— where Rd may form a fused ring with J or with a fused J-R4—W1 ring system, or —C(O)—(CRaRb)n—N(Rc)—S(O)k—(CRaRb)—;
• Z is —(CRaRb)n—C(O)—R7;
• R7 is —OR30, —NR31R32, —NH(CRaRb)n—C(O)—R7, —NHSO2R7 or —(CO)—NH—SO2—R7, or R31;
• each R30 is independently H or alkyl;
• each R31 and R32 is independently H or C1-C6 alkyl optionally substituted with one or more R33, or taken together with the N atom to which they are attached can form a 3- to 7-membered heterocyclic ring;
• each R33 is independently halo, hydroxyl, alkoxy, perhaloalkyl, perhaloalkoxy, carboxyl, —C(O)O—R30, —OR30, —N(R30)2 or heterocyclyl;
• each R4 is independently H, alkyl, alkoxy, or alkyl substituted with one or more R43, halogen, perhaloalkyl, perhaloalkoxy, —CN, —OR40 or —NR41R42;
• each R41 and R42 is independently H, alkyl, —(CH2)n—C(O)O—R40, —C(O)—R40, aryl, heteroaryl;
• or R41 and R42, taken together with the N atom to which they are attached, can form a 3- to 7-membered heterocyclic ring;
• each R43 is independently H, halo, hydroxyl, —NR41R42, or alkoxy;
• W1 is —(CRaRb)il-L1—(CRaRb)j1—R60 or R4;
• or W1 and R4 taken together comprise a 5- or 6-membered carbocyclic or heterocyclic ring fused with the ring to which W1 and R4 are attached and optionally having one, two or three heteroatoms where each such heteroatom is independently selected from O, N, and S, and where any ring atom of such heterocyclic ring may be optionally substituted with one or more —L1—R13 or R13;
• or W1 is a 5- or 6-membered heterocyclic ring fused with a phenyl ring and having one, two or three heteroatoms where each such heteroatom is independently selected from O, N, and S, and where any ring atom of such fused heterocyclic ring and phenyl ring moiety may be optionally substituted with one or more R14;
• L1 is —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR10—, —C(O)NR10—, —N(R10)—(CH2)n—C(O)—,—N(R10)—C(O)—N(R10)—,—N(R10)—S(O)2—, —S(O)2—NR10)—, or —N(S(O)2—(CH2)n—R60)2;
• R60 is R13, —O—(CH2)n—R13, or R10;
• each R10, R11 and R12 is independently H or alkyl;
• R13 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or a fused bicycle or tricycle of any two or three of such ring moieties, or R13 and R10 taken together with the N atom to which they are attached form a heterocyclic ring, where any ring atom of R13 may be optionally substituted with one or more R14 or R15;
• each R14 is independently H, alkyl, halo, hydroxy, cyano, alkoxy, perhaloalkyl, and perhaloalkoxy, —OR10,—(CH2)n—C(O)OR10, —SR10, —SO—R10, —S(O)2—R10), —(CH2)n—NR11R12, —NH—C(O)—(CH2)n—R12, —N(R11)—C(O)—(CH2)n—R12, or —NH(CH2)n—R12;
• R15 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or a fused bicycle of any two of such ring moieties, where any ring atom of R15 may be optionally substituted with one or more R14,
• each R40 is independently H or alkyl;
• each Ra and Rb is independently H, hydroxy, alkyl, or aralkyl optionally substituted with hydroxyl;
• or both Ra and Rb attached to the same carbon are, taken together, oxo, or cycloalkyl;
• each Rc and Rd is independently H, hydroxy, alkyl, —S(O)k—R7 or —C(O)—R7;
• A is cycloalkyl;
• R2 is alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or a fused bicycle of any two of such ring moieties, where any ring atom of R2 may be optionally substituted with one or more R3, each R3 is independently H, alkyl, or perhaloalkyl;
• each k is 2;
• each n is independently 0, 1, 2, 3 or 4;
• and
• each i1 and j1 is independently 0, 1, 2, 3 or 4.